Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA

Procedia in Vaccinology

Volumn 4, Issue , 2011, Pages 78-83

  Rimmelzwaan, Guus F ^a   Kreijtz, Joost H C M ^a   Suezer, Yasemin ^b   Schwantes, Astrid ^b   Osterhaus, Albert D M E ^a   Sutter, Gerd ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Influenza; MVA; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNIZATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INOCULATION; MACACA; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 80053433620     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.07.011     Document Type: Article

References (12)

1. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009, 8:447-454.
2. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. 2010 [cited November 12, 2010]; Available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_10_18/en/index.html.
3. Butler D. Portrait of a year-old pandemic. Nature 2010, 464:1112-1113.
4. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
5. Drexler I., Staib C., Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 2004, 15:506-512.
6. Sutter G., Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003, 3:263-271.
7. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195:1598-1606.
8. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009, 199:405-413.
9. Kreijtz J.H., Suezer Y., de Mutsert G., van Amerongen G., Schwantes A., van den Brand J.M., et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 2009, 4:e7790.
10. Kreijtz J.H., Suzer Y., Bodewes R., Schwantes A., van Amerongen G., Verburgh R.J., et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010, 91:2745-2752.
11. Munster V.J., de Wit E., van den Brand J.M., Herfst S., Schrauwen E.J., Bestebroer T.M., et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009, 325:481-483.
12. van den Brand J.M., Stittelaar K.J., van Amerongen G., Rimmelzwaan G.F., Simon J., de Wit E., et al. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis 2010, 201:993-999.